The Biotech tropicana Systems SMARThivDRmos: Minimizing Cash Waste, Maximizing Life Gains, Increasing Health System Performance.

IMAPCT ANALYSIS

Aboubakar YARI & Venus YARI

------------------

--------------------

Abstract:

SMARThivDRmos is an individual centered HIV drug resistance monitoring technology innovated by the Health Unit of the Biotech tropicana  Systems. Purchasing anti HIV drugs without the profile of drug resistance variants of the virus circulating in a area may incur cash waste. The drugs may not confer any health advantage due to resistance. Numerous studies established a link between HIV drug resistance data and life gains in a population of HIV patients. An effective HIV drug resistance monitoring program requires capacity building of essential infrastructure, to increase health system performance. Here, we analyze the  Biotech tropicana  Systems SMARThivDRmos for impact on the overall development of a country.

Keywords: HIV; Drug Resistance; Patient monitoring; Life Gains; Country Development.

Background:

SMARThivDRmos is an individual centered HIV drug resistance monitoring technology innovated by the Health Unit of the Biotech tropicana  Systems. The main features of SMARThivDRmos are simplicity and optimal cost. We achieve simplicity by transferring complex steps to computer execution. Cost was optimized to the average of the targeted resources poor settings. [1]

Purchasing anti HIV drugs without the profile of drug resistance variants of the virus circulating in a area may incur cash waste. The drugs may not confer any health advantage due to resistance.  Patients infected with drug resistant HIV strains were previously reported.  Selection of resistant variants of the HIV virus after exposure to anti retroviral drugs was also reported; and the World Health Organization recommended a population based survey of resistant variants of the virus circulating in a geographic area, to establish a drug resistance profile. Such a profile could help in drug purchase by avoiding drugs targeted to most common resistant variants of the virus in the area. Blind purchase without availability of drug resistance profile may therefore incur waste. [2]

Numerous studies established a link between availability of HIV drug resistance data and life gains in a population of HIV patients. Numerous studies have established that patients whose physicians have access to HIV drug resistance data show decrease HIV related morbidity and mortality compared to patients whose physicians lack these data. [3]

An effective HIV drug resistance monitoring program requires capacity building of essential infrastructure, to increase health system performance.  HIV drug resistance profiling is a complex process in both respects to equipments for test execution and expertise for test output analysis. Complex and expensive automated HIV genome sequencing are used in the developed world settings. Expert panels recommended cheaper and simpler HIV drug resistance monitoring systems for the developing world settings; and the Biotech tropicana Systems selected the Oligonucleotide Ligation Assay (OLA, USA) and the Enzyme Linked Mini sequence Assay (ELMA, Japan) to demonstrate the feasibility of the recommended three tests standards in monitoring HIV patients in the resource poor settings. [4]

SMARThivDRmos is a simple HIV drug resistance system that carries the characteristics of expert recommended technologies for the resource poor setting in addition to automation to increase output and reduce human input.  Here, we analyze the Biotech tropicana  Systems SMARThivDRmos for impact on the overall development of a developing country.

Discussion:

Business strategies

To achieve high impact we innovate an implementation strategy specific to the Biotech tropicana Systems; our PPPP (4P) program for biotech business operation in the developing world, as applied to SMARThivDRmos. We define the PPPP model as Public-Private-Personal-Partnership for development; with specific tasks assigned to each P partner. [5]

P1: Public. In our model the public sector sets the in country specific rules of operation deducted from expert set rules at global level. Our explorations indicate many developing countries to operate HIV/AIDS programs comprising, free CD4 count (Global Funds), optional viral loads (not operational), no Drug Resistance test.

P2: Private HIV/AIDS programs, BTS: our program is designed to comply with the international standards as performed in the developed world settings, comprising CD4 count , Viral Load, and Drug Resistance tests [4]. We levy a fee for services.

P3: Personal: Personal responsibility of the patients. BTS Insurance program set an account for all registered client patients. Patients can save in account in any amount any time before test is required. Patient is tested on test date set by medical expert upon presentation of insurance card with balance equal or more to test fee.

P4: Partnership: the BTS program is designed not to interfere with the public program, but to create additional opportunities for the patients (life gains). It is up to the patient to choose between the public and the private programs to monitor health status. Our democratic program not only creates new opportunities for the patients but also contributes to the control of the diseases for the country (development gains). The longer the patients live, the more tests they will need, the more money the bts make; a demonstration of the bts compassionate capitalism philosophy. Our programs are designed to make profit by contributing to life gains and development gains in the host country. Policy 33.Biotech tropicana Systems.

INNOVATION: Personal responsibility. Patients is responsible of own health. Decision to which of the three tests the patient received is moved from public programs to patients themselves. The patients take control of their own destiny. Insurance program is coordinated by Biotech tropicana,IncFINANCIAL. For details of insurance program. See at A. YARI & V. YARI; SMARThiv3TestsMobileLAB: The Mobile Life Box. Available at African Specific Literature Database (ASLD)  at www.btsabic.ucoz.com.  [6]

SMARThivGLOBALmos as applied to SMARThivDRmos.

At implementation level, we included in the SMARThivGLOBALmos package, the SMARThivINSURANCE program, a subcomponent of the Biotech tropicana Systems SMARThealthinsurancePROGRAM. The Clinton Foundation  HIV/AIDS program (CHAI) previously demonstrated the importance of coordination in HIV/AIDS implementation. The CHAI innovated a marketing strategy that applied diplomacy principles to coordinate access to medicines between Biotech company providers and developing world consumer governments. Implication of CHAI in the implementation process permit many poor governments to comply with applicable guidelines. We have not been successful in being accepted as other Biotech companies in the CHAI program, in a manner that would be consistent with internal policies of the Biotech tropicana Systems. Policy 29. Biotech tropicana Systems. We innovate our own implementation program to coordinate the implementation of the Biotech tropicana Systems SMARThivTECHS: SMARThivGLOBALmos. An innovative component of our SMARThivGLOBALmos is the inclusion of our SMARThivINSURANCE program. [7]

Synthesis:

Our program will generate viral load and drug resistance data of poor patients from the developing world. These data will be systematically organized in SABIC database of Biotech tropicana,IncAU, for sharing with international databases such as the Stanford university database in USA and the European databases in EU. Our program is designed to close the divide between the rich patients of the developed world and the poor patients of the developing world, and integrate data from developing world in the international system to be considered in research programs for improvements. So far the B subtype of the HIV virus which is common in the western world is the model for many research studies. Data from the non B subtypes which are common in the developing world are not included in these studies. Why? Because these data are simply not available. The Biotech tropicana Systems HIV/AIDS program is designed to change ‘change’ that fact. The compliance of our program with international standards permit the integration of the developing world HIV/AIDS programs in the global HIV/AIDS programs. See Juma et al; developing countries must comply with international standards to benefit from the global pool of knowledge. [8]

Here, we design the Biotech tropicana,IncHEALTH HIV/AIDS program for the developing world to test and demonstrate our ‘triangle hypothesis’, AU-EU-US toward an equilateral triangle in commercialization of biotechnologies, with Biotech tropicana Systems pulling the developing world. See Radelet S in ‘from pushing reforms to pulling reforms’ . [9]

Development gains. Our program as designed Contributes to the development of the host country. Reduced morbidity will reduce demand on already weak developing world health system, and keep HIV patients on their jobs to contribute to the development of their countries, instead of becoming social welfare recipients on their countries budget.

Generating market and creating jobs. The program also contributes to generating market and creating jobs in the host country. The Biotech tropicana,Inc HEALTH unit does not develop a medicine capacity. We partner with local medical capacity, preferentially private, for a fee, for implementation of our programs requiring capacity in medicine.

Life gains. The three tests standard was demonstrated to  extend life of the patient in countries in which its  previously implemented. The three tests standard therefore contribute to stabilizing families of HIV patients. As previously demonstrated the HIV affected parent lives long enough to see the children grow to adulthood, thereby reducing the number of HIV related orphans and having HIV positive parents being emotionally involved in their children’s life on daily basis.

Conclusion:

SMARThivDRmos is by now at the second development phase in the Biotech tropicana Systems. A process protocol is developed for immediate implementation where needed. Considering the availability of funds and the complexity of the test, public frameworks gave a lower priority to hiv drug resistance testing in developing countries. CD4 count has highest priority, followed by  viral load test. We design our protocols for implementation through the private sector, as a single three tests package; giving the poor patients an opportunity to take control of their own destiny. The impact of our approach in increasing life gains for the patients, development gains for the country, and wealth gains for the Biotech tropicana Systems is consistent with our compassionate capitalism philosophy.

References:

[1] Yari et al; SMARThivDRmos. Available at http://btsabic.ucoz.com/publ/asld_african_specific_literature_database/1-1-0-7

[2] World Health Organization. 2003, Available  guidelines at http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf

 [3] Shafer,W. R. (2002),Ghttp://btropicanaforum.ucoz.com/publ/0-0-0-57-13enotypic Testing for Human Immunodeficiency Virus Type I Drug Resistance, Clin. Microb. Rev. 15:2, 247-277

[4] Yari et al; SMARThivPACK at http://btsabic.ucoz.com/publ/asld_african_specific_literature_database/1-1-0-7

[5] Yari et al; PPPP. Available at http://btlitigator.ucoz.com/publ/smart4p_partnership_model_project/1-1-0-1

[6] A. Yari & V. Yari; SMARthiv3TestsMobileLaB: The Mobile Life Box. Available at http://btsabic.ucoz.com/publ/asld_african_specific_literature_database/1-1-0-7

[7] A. Yari & M. Yari; SMARThivGLOBALmos. Available at http://btitechtrials.ucoz.com/publ/smarthivglobalmos_trials_home/1-1-0-13

 [8] Juma et  al; Innovation: Applying knowledge In Development. UN Millennium Project at http://www.unmillenniumproject.org/documents/Science-complete.pdf

[9] Steve Radelet; From pushing reforms to pulling reforms; on the US Millennium Challenge Account. Center for Global Development. Available at http://www.cgdev.org/publication/pushing-reforms-pulling-reforms-role-challenge-programs-foreign-aid-policy-working-paper